Notizie e Video - CRYOPORT INC. - Pagina 5

Cryoport Reports Record Third Quarter and Nine Months Revenue for 2021 - Third quarter revenue increased 407% year over year, reaching $56.7 million; Nine Months 2021 revenue $166.2 million - Organic Revenue Growth of 38% coupled with continuing strong performance by MVE Biological Solutions and CRYOPDP - Now supporting a record 582 clinical trials and eight commercial therapies in regenerative medicine PR Newswire NASHVILLE, Tenn., Nov. 4, 2021 NASHVILLE, Tenn. , Nov. 4, 2021 /PRNewswire/ --...

CRYOPDP, a Cryoport Company, Receives 2021 Europe Bioprocessing Excellence Award from IMAPAC CRYOPDP, a Cryoport Company, named as 'The Company You Need to Watch Out For in 2022' PR Newswire NASHVILLE, Tenn., Oct. 29, 2021 NASHVILLE, Tenn. , Oct. 29, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that its wholly-owned operating company, CRYOPDP , a...

Cryoport to Report Third Quarter 2021 Financial Results on November 4, 2021 PR Newswire NASHVILLE, Tenn., Oct. 28, 2021 NASHVILLE, Tenn. , Oct. 28, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021 after U.S. markets close. In...

Cryoport and Mitsubishi Logistics Corporation Partner to Bring Temperature-Controlled Supply Chain Solutions to Asia-Pacific PR Newswire NASHVILLE, Tenn., Aug. 25, 2021 NASHVILLE, Tenn. , Aug. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene therapy markets, and Mitsubishi Logistics...

Cryoport Reports Record Second Quarter 2021 Revenue - Record Revenue for Second Quarter of 2021 of $56.2 million - Revenue increased 498% year over year, with continuing strong performance by MVE Biological Solutions and CRYOPDP - Organic Revenue Growth of 55% - Supporting a record 561 clinical trials and eight commercial therapies in regenerative medicine PR Newswire NASHVILLE, Tenn., Aug. 5, 2021 NASHVILLE, Tenn. , Aug. 5, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the...

Cryoport to Report Second Quarter 2021 Financial Results on August 5, 2021 PR Newswire NASHVILLE, Tenn., July 29, 2021 NASHVILLE, Tenn. , July 29, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021 after U.S. markets close. In addition to...

Cellenkos® Selects Cryoport to Support On-Demand, Flexible COVID-19 Therapy Shipments to Patients in Need PR Newswire NASHVILLE, Tenn., June 22, 2021 NASHVILLE, Tenn. , June 22, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Cellenkos ® , Inc., a privately held, clinical-stage biotechnology company, has selected Cryoport to provide a staged,...

Cryoport Further Expands its Asia Pacific Operations with New Global Logistics Center in Singapore CRYOPDP named Best Clinical Trial Logistics Provider at the Asia Pacific Bioprocessing Excellence Awards 2021 PR Newswire NASHVILLE, Tenn., May 19, 2021 NASHVILLE, Tenn. , May 19, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that its wholly owned...

Cryoport Expands Global Supply Chain Network with Belgium Acquisition Acquisition will expand Cryoport's presence in the EMEA region and is expected to be immediately accretive PR Newswire NASHVILLE, Tenn., May 18, 2021 NASHVILLE, Tenn. , May 18, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene...

LabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial PR Newswire JOHNSON CITY, Tenn. and NASHVILLE, Tenn., May 6, 2021 JOHNSON CITY, Tenn. and NASHVILLE, Tenn. , May 6, 2021 /PRNewswire/ -- LabConnect, Inc. and Cryoport, Inc. (NASDAQ: CYRX) today announced a partnership to provide comprehensive logistics support for an upcoming Phase I/II clinical trial sponsored by Triumvira Immunologics Inc., a privately held biopharmaceutical company...

Cryoport Revenue Climbs to $53.3 Million for First Quarter 2021 - Revenue increased 445% compared with Q1 2020, with acquisitions of MVE Biological Solutions and CRYOPDP driving significant growth - Organic revenue growth of 35% compared with Q1 2020 - A record 543 clinical trials in regenerative medicine are supported by Cryoport - Cryoport now supports seven commercial therapies, including bluebird bio's and Bristol Myer Squibb's CAR-T therapy Abecma® and Bristol Myers Squibb's BREYANZI® PR...

Cryoport to Report First Quarter 2021 Financial Results on May 4, 2021 PR Newswire NASHVILLE, Tenn., April 27, 2021 NASHVILLE, Tenn. , April 27, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the first quarter ended March 31, 2021 on Tuesday, May 4, 2021 after U.S. markets close. In addition to the...

Cryoport Acquires Temperature-Controlled Logistics Provider in Australia Acquisition Further Expands Cryoport's Presence in Asia-Pacific Region to Address Increased Clinical Trial Activity Worldwide PR Newswire NASHVILLE, Tenn., April 6, 2021 NASHVILLE, Tenn. , April 6, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced it has acquired Critical Transport...

Cryoport Announces Appointment of Linda Baddour to its Board of Directors Ms. Baddour brings over twenty years of experience across healthcare, life sciences and pharmaceuticals PR Newswire NASHVILLE, Tenn., March 3, 2021 NASHVILLE, Tenn. , March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a...

Cryoport Reports Record Results for Full Year 2020 - Fourth quarter revenue increased 423% to $48.4 million, annual revenue increased 132% to $78.7 million - Organic growth in revenue was 36% for the fourth quarter and 26% for the full year 2020 - Cryoport is supporting a total of 528 clinical trials, and six commercial therapy agreements, including the global launch of Bristol-Myers Squibb's BREYANZI® - In Q4 2020, Cryoport closed the acquisitions of MVE Biological Solutions and CRYOPDP,...

Cryoport to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 1, 2021 PR Newswire NASHVILLE, Tenn., Feb. 25, 2021 NASHVILLE, Tenn. , Feb. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and fiscal year ended December 31, 2020 on Monday, March 1, 2021 after...

Cryoport Launches Environmental, Social, and Governance (ESG) Program - Over 118 million pounds of Green House Gas emissions avoided in 2020 - Over 99.8% success rate on deliveries resulted in over 9,500 additional patients treated and potential of additional 690 live births via CryoStork® reproductive medicine solution PR Newswire NASHVILLE, Tenn., Feb. 25, 2021 NASHVILLE, Tenn. , Feb. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in...

Cryoport Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters to Purchase Additional Shares PR Newswire NASHVILLE, Tenn., Jan. 25, 2021 NASHVILLE, Tenn. , Jan. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the closing of an underwritten public offering of 4,356,059 shares of its common stock, at a public...

Cryoport Announces Pricing of Public Offering of Common Stock PR Newswire NASHVILLE, Tenn., Jan. 20, 2021 NASHVILLE, Tenn. , Jan. 20, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the pricing of its underwritten public offering of an aggregate of 3,787,878 newly issued shares of common stock at a public offering price of $66.00 per share. In...

Cryoport Announces Proposed Public Offering of Common Stock PR Newswire NASHVILLE, Tenn., Jan. 19, 2021 NASHVILLE, Tenn. , Jan. 19, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it intends to offer $200 million of shares of common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be...